ERBB2 and neoplasm: T-DXd selectively targets HER2-positive tumor cells and induces cell lysis, leading to the release of tumor-associated antigens and remodeling of the tumor microenvironment, thereby enhancing tumor immunogenicity and facilitating antigen presentation (10).